Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trialBenjamin Z. Leder, Sherri‐Ann M. Burnett‐Bowie, Joy N. Tsai et al.|The Lancet|2015Cited by 574
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trialJoy N. Tsai, Benjamin Z. Leder, Elizabeth McKay et al.|The Lancet|2013Cited by 491
Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled TrialBenjamin Z. Leder, Robert M. Neer, Joy N. Tsai et al.|The Journal of Clinical Endocrinology & Metabolism|2014Cited by 278
Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA-HRpQCT StudyJoy N. Tsai, Benjamin Z. Leder, Alexander V. Uihlein et al.|Journal of Bone and Mineral Research|2014Cited by 145
Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study)Joy N. Tsai, Benjamin Z. Leder, Alexander V. Uihlein et al.|The Journal of Clinical Endocrinology & Metabolism|2016Cited by 120